Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA007264 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA007264, RRID:AB_1080053
- Product name
- Anti-SSTR2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human SSTR2, Gene description: somatostatin receptor 2, Validated applications: ICC, WB, IHC, Uniprot ID: P30874, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC)
Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice
Recuero E, Lázaro S, Lorz C, Enguita A, Garcia-Escudero R, Santos M
International Journal of Molecular Sciences 2023;24(20):15284
International Journal of Molecular Sciences 2023;24(20):15284
Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
Tran C, Borbon L, Mudd J, Abusada E, AghaAmiri S, Ghosh S, Vargas S, Li G, Beyer G, McDonough M, Li R, Chan C, Walsh S, Wadas T, O’Dorisio T, O’Dorisio M, Govindan R, Cliften P, Azhdarinia A, Bellizzi A, Fields R, Howe J, Ear P
Cancers 2022;14(8):1910
Cancers 2022;14(8):1910
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
Hennigs JK, Müller J, Adam M, Spin JM, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S
PloS one 2014;9(7):e100469
PloS one 2014;9(7):e100469
ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy
Minner S, Enodien M, Sirma H, Luebke A, Krohn A, Mayer P, Simon R, Tennstedt P, Müller J, Scholz L, Brase J, Liu A, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
Clinical Cancer Research 2011;17(18):5878-5888
Clinical Cancer Research 2011;17(18):5878-5888
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice
Erlandsson A, Forssell-Aronsson E, Seidal T, Bernhardt P
EJNMMI Research 2011;1(1):19
EJNMMI Research 2011;1(1):19
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Recombinant expression validation
- Main image
- Experimental details
- Western blot analysis in control (vector only transfected HEK293T lysate) and sSTR2 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY400438).
- Sample type
- Human
- Protocol
- Protocol
